WHO ICTRP trial
A double-blind, randomized, placebo-controlled, sequential ascending single-dose…
KCT0000539 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0000539 |
|---|---|
| Public title | A double-blind, randomized, placebo-controlled, sequential ascending single-dose study to evaluate the pharmacokinetic and tolerability profiles of teriflunomide in healthy Korean subjects |
| Scientific title | A double-blind, randomized, placebo-controlled, sequential ascending single-dose study to evaluate the pharmacokinetic and tolerability profiles of teriflunomide in healthy Korean subjects |
| Primary sponsor | Sanofi-Aventis Korea |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase1 |
| Countries | Korea, Republic of |
| Conditions | Diseases of the nervous system |
| Interventions | Drug : The investigational medicinal product of this study is teriflunomide or matching placebo.Single dose of teriflunomide 7 mg or matching placebo for group 1, single dose of teriflunomide 14mg or matching placebo for group 2 and single… |
| Registration date | Sep 20, 2012 |
| Target size | 36 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: